Evidence map›Paper›PMID 22516424›Full record

ArticleEuropean journal of medicinal chemistry2012

The synthesis of 2,5-bis(4-amidinophenyl)thiophene derivatives providing submicromolar-range inhibition of the botulinum neurotoxin serotype A metalloprotease.

Igor Opsenica, Vuk Filipovic, Jon E Nuss, Laura M Gomba, Dejan Opsenica, James C Burnett, Rick Gussio, Bogdan A Solaja, Sina Bavari

Open access · greenAbstract read
In one paragraph

Article in European journal of medicinal chemistry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 2 countries.

Igor OpsenicaFaculty of Chemistry, University of Belgrade, Studentski trg16, PO Box 51, Belgrade, Serbia.
Vuk Filipovic
Jon E Nuss
Laura M Gomba
Dejan Opsenica
James C Burnett
Rick Gussio
Bogdan A Solaja
Sina Bavari
University of Belgrade · RSNational Cancer Institute · USUnited States Army Medical Research Institute of Infectious Diseases · USTarget (United States) · US

Funding

Second Generation Small Molecule Inhibitors of Botulinum NeurotoxinsU01AI082051 · NIAID · GENEVA FOUNDATION · PI BAVARI, SINA · 2009 to 2013
$4.5M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS 5-U01AI082051-02NIAID NIH HHS U01 AI082051
6 · The paper itself

Abstract

Botulinum neurotoxins (BoNTs), composed of a family of seven serotypes (categorized A-G), are the deadliest of known biological toxins. The activity of the metalloprotease, light chain (LC) component of the toxins is responsible for causing the life-threatening paralysis associated with the disease botulism. Herein we report significantly more potent analogs of novel, lead BoNT serotype A LC inhibitor 2,5-bis(4-amidinophenyl)thiophene (K(i) = 10.88 μM ± 0.90 μM). Specifically, synthetic modifications involved simultaneously replacing the lead inhibitor's terminal bis-amidines with secondary amines and the systematic tethering of 4-amino-7-chloroquinoline substituents to provide derivatives with K(i) values ranging from 0.302 μM (± 0.03 μM) to 0.889μM (± 0.11 μM).

Indexed as

Botulinum Toxins, Type AChemistry Techniques, SyntheticDose-Response Relationship, DrugProtease InhibitorsThiophenesBotulinum Toxins, Type AProtease InhibitorsThiophenes

Identifiers

PMID22516424
PMCPMC3361628
OpenAlexW2012536583

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.